Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot

BMJ Open

Volumn 6, Issue 1, 2016, Pages

  Lu, Jiapeng ^a   Xuan, Si ^b,c   Downing, Nicholas S ^b   Wu, Chaoqun ^a   Li, Li ^a   Krumholz, Harlan M ^b,c,d   Jiang, Lixin ^a  

^a FUWAI HOSPITAL   (China)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c YALE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINA; CHOLESTEROL BLOOD LEVEL; COMMUNITY LIVING; DIAGNOSTIC TEST ACCURACY STUDY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL HISTORY; PATIENT COUNSELING; PILOT STUDY; PRACTICE GUIDELINE; PRELIMINARY COMMUNICATION; PREVALENCE; PROGNOSIS; PROTOCOL COMPLIANCE; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVAL; TELEPHONE INTERVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; AGE DISTRIBUTION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOL; CLINICAL TRIAL; COUNSELING; EARLY DIAGNOSIS; HEALTH CARE QUALITY; HEART RATE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT CARE; PHYSICAL EXAMINATION; PHYSIOLOGY; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHINA; CLINICAL PROTOCOLS; COUNSELING; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH STATUS; HEART RATE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PATIENT-CENTERED CARE; PHYSICAL EXAMINATION; QUALITY ASSURANCE, HEALTH CARE; SEX DISTRIBUTION;

EID: 84960435906     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010200     Document Type: Article

References (50)

1. National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington DC: National Academies Press, 2011.
2. Bi Y, Jiang Y, He J, et al. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol 2015;65:1013-25.
3. He J, Gu D, Chen J, et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet 2009;374:1765-72.
4. Odegaard AO, Koh WP, Yuan JM, et al. Western-style fast food intake and cardiometabolic risk in an Eastern country. Circulation 2012;126:182-8.
5. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124-34.
6. Popkin BM. Synthesis and implications: China's nutrition transition in the context of changes across other low-and middle-income countries. Obes Rev 2014;15(Suppl 1):60-7.
7. Wang X-Q, Chen P-J. Population ageing challenges health care in China. Lancet 2014;383:870.
8. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 2010;3:243-52.
9. Wang S, Marquez P, Langenbrunner J. Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases. Washington: The World Bank, 2011.
10. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014;129(25-Suppl-2): S76-99.
11. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for prevention of cardiovascular diseases]. Zhonghua Xin Xue Guan Bing Za Zhi 2011;39:3-22.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
14. Tonkin A, Aylward P, Colquhoun D, et al. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
15. Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.
17. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
18. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013;309:1014-21.
19. Kodama S, Tanaka S, Heianza, Y, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 2013;36:471-9.
20. Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on cardiovascular disease and mortality: evidence from the Framingham Heart Study. Heart 2013;99:649-54.
21. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ2007;334:885-8.
22. Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999;69:632-46.
23. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997;26:1-13.
24. Berger JS, Jordan CO, Lloyd-Jones D, et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169-77.
25. American College of Cardiology. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1995;96:957-1047.
26. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584-636.
27. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59.
28. Wang S, Xu L, Jonas JB, et al. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS ONE2011;6: e17326.
29. Wang H, Zhang X, Zhang J, et al. Factors associated with prevalence, awareness, treatment and control of hypertension among adults in Southern China: a community-based, cross-sectional survey. PLoS ONE2013;8:e62469.
30. Wei X, Zou G, Yin J, et al. Characteristics of high risk people with cardiovascular disease in Chinese rural areas: clinical indictors, disease patterns and drug treatment. PLoS ONE2013;8: e54169.
31. Dharmarajan K, Li J, Li X, et al. The China Patient-Centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective study of acute myocardial infarction: study design. Circ Cardiovasc Qual Outcomes 2013;6:732-40.
32. Li J, Dharmarajan K, Li X, et al. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) retrospective study of coronary catheterisation and percutaneous coronary intervention. BMJ Open 2014;4:e004595.
33. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5.
34. World Health Organization. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva: WHO, 2007.
35. World Health Organization/International Society of Hypertension. WHO/ISH Risk prediction charts for 14 WHO epidemiological sub-regions. Geneva: WHO, 2007.
36. Bidgood WD, Horii SC, Prior FW, et al. Understanding and using DICOM, the data interchange standard for biomedical imaging. J Am Med Inform Assoc 1997;4:199-212.
37. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol2011;40: 1652-66.
38. Li Q, Babor TF, Hao W, et al. The Chinese translations of Alcohol Use Disorders Identification Test (AUDIT) in China: a systematic review. Alcohol Alcohol 2011;46:416-23.
39. Zhao Y, Strauss J, Yang G, et al. China Health and Retirement Longitudinal Study-2011-2012 national baseline users' guide. Beijing: National School of Development, Peking University, 2013.
40. Wang HM, Patrick DL, Edwards TC, et al. Validation of the EQ-5D in a general population sample in urban China. Qual Life Res 2012;21:155-60.
41. Strauss J, Lei X, Park A, et al. Health outcomes and socio-economic status among the elderly in Gansu and Zhejiang Provinces, China: evidence from the CHARLS pilot. J Popul Ageing 2010;3:111-42.
42. Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012;33:213-20.
43. Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005;112:658-65.
44. Wang Y, Mi J, Shan XY, et al. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007;31:177-88.
45. Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008;118:2679-86.
46. Yang G, Fan L, Tan J, et al. Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 1999;282:1247-53.
47. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
48. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
49. Manolio TA, Weis BK, Cowie CC, et al. New models for large prospective studies: is there a better way? Am J Epidemiol 2012;175:859-66.
50. Leitsalu L, Haller T, Esko T, et al. Cohort profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2015;44:1137-47.